URGN · UroGen Pharma Ltd.
$48.22
+0.10 (+0.21%)
At close · Aug 14
Going-concern doubt
— cleared Aug 5, 2026
The latest filing states the doubt was alleviated.
“Based on our cash and cash equivalents and marketable securities as of June 30, 2026, together with management's cash flow projections, we believe we have sufficient cash and cash equivalents to fund our operations beyond one year from the issuance of our condensed consolidated financial statements appearing elsewhere in this Quarterly Report.”View the 10-Q filed Aug 5, 2026
Market Cap
$2.36B
Shares
48.88M
UroGen Pharma Ltd. Earnings Call Transcripts
Every quarterly earnings call for UroGen Pharma Ltd. (URGN) — the full transcript with speaker labels, the audio replay, AI call highlights and a management-tone score, plus the matching 8-K earnings release and the quarter's 10-Q or 10-K. Investor days and conferences appear here too.
Revenue & result across quarters
Revenue Net income YoY up YoY down artefacts
▲41.8%
$16.10M
−$25.83M
'22 Q3
22-11-10
▲11.9%
$18.09M
−$28.87M
'22 Q4
23-03-22
▲26.7%
$17.19M
−$30.21M
'23 Q1
23-05-11
▲27.3%
$21.14M
−$24.14M
'23 Q2
23-08-10
▲29.5%
$20.85M
−$21.88M
'23 Q3
23-11-14
▲30.1%
$23.53M
−$26.02M
'23 Q4
24-03-14
▲9.2%
$18.78M
−$32.29M
'24 Q1
24-05-13
▲3.4%
$21.85M
−$33.40M
'24 Q2
24-08-13
▲20.9%
$25.20M
−$23.67M
'24 Q3
24-11-06
▲4.4%
$24.57M
−$37.51M
'24 Q4
25-03-10
▲7.8%
$20.25M
−$43.84M
'25 Q1
25-05-12
▲10.8%
$24.21M
−$49.94M
'25 Q2
25-08-07
▲9%
$27.48M
−$33.35M
'25 Q3
25-11-06
▲54%
$37.84M
−$26.36M
'25 Q4
26-03-02
▲151.6%
$50.96M
−$23.57M
'26 Q1
26-05-06
LATEST
▲199.2%
$72.46M
−$14.35M
'26 Q2
26-08-05
Earnings call
FY26 · Q2
2026-08-05
UroGen Pharma Ltd. Q2 FY2026 Earnings Call
Confident tone
Pipeline progression (UGN-103, UGN-104, UGN-501)
Envision Phase 3 durability data
Community practice adoption expansion
Revenue
$72.46M
▲ 199.2% YoY Gross margin
90.9%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-05-19
HC Wainwright 4th Annual BioConnect Investor Conference
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q1
2026-05-06
UroGen Pharma Ltd. Q1 FY2026 Earnings Call
Confident tone
ZUSDURI launch momentum
JELMYTO outlook
Community setting adoption
Revenue
$50.96M
▲ 151.6% YoY Gross margin
91.9%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q4
2026-03-02
UroGen Pharma Ltd. Q4 FY2025 Earnings Call
Confident tone
Zysturi commercial launch
UGN-103 next-generation pipeline
UGN-104 Jelmyto next-generation
Revenue
$37.84M*
▲ 54% YoY Gross margin
91.3%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY25 · Q3
2025-11-06
UroGen Pharma Ltd. Q3 FY2025 Earnings Call
Positive tone
ZUSDURI launch
JELMYTO commercial performance
UGN-103 next-generation mitomycin
Revenue
$27.48M
▲ 9% YoY Gross margin
88.1%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-08-07
UroGen Pharma Ltd. Q2 FY2025 Earnings Call
Confident tone
Patient demand and eligible patient pool
Zesturi (Jesduvriq) commercial launch and revenue growth
Physician adoption and KOL feedback
Revenue
$24.21M
▲ 10.8% YoY Gross margin
85.3%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-05-12
UroGen Pharma Ltd. Q1 FY2025 Earnings Call
Confident tone
UGN-102 regulatory progress and ODAC
UGN-102 commercial launch readiness
JELMYTO commercial performance
Revenue
$20.25M
▲ 7.8% YoY Gross margin
88.5%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-03-10
UroGen Pharma Ltd. Q4 FY2024 Earnings Call
Confident tone
UGN-102 NDA and regulatory progress
JELMYTO commercial performance
ENVISION trial data and durability
Revenue
$24.57M
▲ 4.4% YoY Gross margin
89.9%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-11-06
UroGen Pharma Ltd. Q3 FY2024 Earnings Call
Confident tone
UGN-102 NDA progress and potential approval
JELMYTO commercial performance
Advisory committee preparation
Revenue
$25.20M
▲ 20.9% YoY Gross margin
90.3%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-08-13
UroGen Pharma Ltd. Q2 FY2024 Earnings Call
Positive tone
UGN-102 pivotal data and NDA submission
JELMYTO commercial performance
Gross-to-net and reimbursement headwinds
Revenue
$21.85M
▲ 3.4% YoY Gross margin
89.8%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-05-13
UroGen Pharma Ltd. Q1 FY2024 Earnings Call
Confident tone
UGN-102 regulatory and commercial opportunity
JELMYTO commercial performance
High-grade disease and UGN-301 program
Revenue
$18.78M
▲ 9.2% YoY Gross margin
90.8%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2024-03-14
UroGen Pharma Ltd. Q4 FY2023 Earnings Call
Confident tone
UGN-102 regulatory and commercial opportunity
Clinical trial data (ATLAS, ENVISION, OPTIMA)
JELMYTO commercial performance
Revenue
$23.53M
▲ 30.1% YoY Gross margin
90.3%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-11-14
UroGen Pharma Ltd. Q3 FY2023 Earnings Call
Revenue
$20.85M
▲ 29.5% YoY Gross margin
88.6%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-08-10
UroGen Pharma Ltd. Q2 FY2023 Earnings Call
Revenue
$21.14M
▲ 27.3% YoY Gross margin
88.4%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q1
2023-05-11
UroGen Pharma Ltd. Q1 FY2023 Earnings Call
Revenue
$17.19M
▲ 26.7% YoY Gross margin
86.8%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2023-03-22
UroGen Pharma Ltd. Q4 FY2022 Earnings Call
Revenue
$18.09M*
▲ 11.9% YoY Gross margin
87.5%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY22 · Q3
2022-11-10
UroGen Pharma Ltd. Q3 FY2022 Earnings Call
Revenue
$16.10M
▲ 41.8% YoY Gross margin
87.5%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q2
2022-08-11
UroGen Pharma Ltd. Q2 FY2022 Earnings Call
Revenue
$16.60M
▲ 27.4% YoY Gross margin
88.9%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q1
2022-05-10
UroGen Pharma Ltd. Q1 FY2022 Earnings Call
Revenue
$13.56M
▲ 81.2% YoY Gross margin
88.8%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q4
2022-03-21
UroGen Pharma Ltd. Q4 FY2021 Earnings Call
Revenue
$16.17M*
Gross margin
90.2%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY21 · Q3
2021-11-15
UroGen Pharma Ltd. Q3 FY2021 Earnings Call
Revenue
$11.35M
▲ 228% YoY Gross margin
89.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q2
2021-07-14
UroGen Pharma Ltd. Q2 FY2021 Earnings Call
Revenue
$13.03M
▲ 3403.2% YoY Gross margin
89.1%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q1
2021-05-13
UroGen Pharma Ltd. Q1 FY2021 Earnings Call
Revenue
$7.49M
Gross margin
88.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q4
2021-03-18
UroGen Pharma Ltd. Q4 FY2020 Earnings Call
Results not yet reported
Audio
Transcript
Slides
8-K10-K
Earnings call
FY20 · Q3
2020-11-09
UroGen Pharma Ltd. Q3 FY2020 Earnings Call
Revenue
$3.46M
Gross margin
91.1%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q2
2020-08-10
UroGen Pharma Ltd. Q2 FY2020 Earnings Call
Revenue
$372,000
▲ 1966.7% YoY Gross margin
87.1%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q1
2020-03-31
UroGen Pharma Ltd. Q1 FY2020 Earnings Call
Results not yet reported
Audio
Transcript
Slides
8-K10-Q
Showing 1–27 of 27 earnings calls
Key facts
CIK
1668243
CUSIP
M96088105
13F (30d)
187 filings
183 filers
Visit website
Investor relations